Atopic dermatitis is one of the most common chronic inflammatory skin diseases of childhood. Affecting approximately 15–20% of children worldwide, this condition can significantly impact both children's quality of life and families' daily routines. Thanks to advances in dermatology in 2026, treatment options have expanded considerably.
What Is Atopic Dermatitis?
Atopic dermatitis is a chronic form of eczema that develops as a result of impaired skin barrier function and an overactive immune response. Genetic predisposition, environmental factors, and an imbalance in the skin microbiome all play important roles in the onset and flare-ups of the condition. In children, it typically begins between the first six months and five years of age, presenting as redness, itching, and dryness on the cheeks and in the folds of the elbows and knees.
Current Diagnostic Criteria
Diagnosis is largely based on clinical evaluation. Chronic or recurrent pruritic eczematous lesions, a characteristic distribution pattern, and a personal or family history of atopic disease are among the core diagnostic criteria. As of 2026, biomarker-based diagnostic methods are also beginning to enter clinical practice; serum thymic stromal lymphopoietin levels in particular are proving helpful in determining disease severity.
Core Principles of Treatment
Skin Care and Moisturisers
The cornerstone of treatment is regular and correct use of moisturisers. Ceramide-containing moisturisers strengthen the skin barrier, while fragrance-free and hypoallergenic formulations minimise the risk of irritation. Application at least twice daily — especially to damp skin immediately after bathing — is recommended.
Topical Treatments
For mild to moderate cases, topical corticosteroids remain the first-line treatment. However, side effects such as skin thinning must be kept in mind with long-term use. Topical calcineurin inhibitors — tacrolimus and pimecrolimus — are preferred particularly in areas such as the face and neck where steroid use should be limited.
By 2026, topical JAK inhibitors are being used increasingly in children; ruxolitinib cream represents one of the important options in this field.
Systemic Treatments
For moderate to severe cases, biological agents have revolutionised treatment. Dupilumab is approved for use in children aged six months and above, controlling inflammation by targeting the IL-4 and IL-13 signalling pathways. Tralokinumab and next-generation JAK inhibitors have also entered clinical use with paediatric indications.
Avoiding Trigger Factors
Allergens, hot environments, synthetic fabrics, stress, and infections can all trigger flare-ups. Choosing soft cotton-based clothing, maintaining balanced indoor humidity, and identifying and removing potential dietary allergens are critically important in disease management.
Family Education and Psychological Support
Educating the family is indispensable in managing atopic dermatitis, a chronic condition. Breaking the itch-scratch cycle, maintaining regular sleep patterns, and supporting the child's self-confidence directly affect treatment success.
At Virtuana Clinic, personalised treatment plans are developed for your child's skin health and the most current dermatological approaches are applied. Please contact us for pricing and to book an expert consultation.
This article is for informational purposes only. Please consult a qualified physician for treatment decisions.